Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | NMT1 | P30419 | 5/20 | 0.49 |
| ▸ | NMT2 | O60551 | 4/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.44 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30881181 | 1.00 | GSR (0.50) | GSRFOLH1NMT1NMT2TLR2 | |
| SCHEMBL10522423 | 0.98 | GSR (0.51) | GSRFOLH1NMT1NMT2TLR2 | |
| SCHEMBL10522441 | 0.98 | GSR (0.51) | GSRFOLH1NMT1NMT2TLR2 | |
| SCHEMBL30581338 | 0.97 | GSR (0.50) | GSRFOLH1NMT1NMT2TLR2 | |
| SCHEMBL29943324 | 0.97 | GSR (0.50) | GSRFOLH1NMT1NMT2TLR2 | |
| SCHEMBL29592035 | 0.97 | GSR (0.50) | GSRFOLH1NMT1NMT2TLR2 | |
| SCHEMBL29630424 | 0.97 | GSR (0.50) | GSRFOLH1NMT1NMT2TLR2 | |
| SCHEMBL30039547 | 0.95 | GSR (0.51) | GSRFOLH1NMT1NMT2TLR2 | |
| SCHEMBL30277638 | 0.95 | GSR (0.51) | GSRFOLH1NMT1NMT2TLR2 | |
| SCHEMBL29669224 | 0.94 | FOLH1 (0.50) | GSRFOLH1NMT1NMT2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2024092028-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | GSR 4364/4885FOLH1 227/4885NMT1 2776/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | GSR 4512/4885FOLH1 267/4885NMT1 849/4885 |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | MYD88, ICOS, CD4 | GSR 4158/4885FOLH1 1592/4885NMT1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.